NTS-105 decreased cell death and preserved long-term potentiation in an in vitro model of moderate traumatic brain injury

Exp Neurol. 2023 Nov 8:114608. doi: 10.1016/j.expneurol.2023.114608. Online ahead of print.ABSTRACTTraumatic brain injury (TBI) is a major cause of hospitalization and death. To mitigate these human costs, the search for effective drugs to treat TBI continues. In the current study, we evaluated the efficacy of the novel neurosteroid, NTS-105, to reduce post-traumatic pathobiology in an in vitro model of moderate TBI that utilizes an organotypic hippocampal slice culture. NTS-105 inhibited activation of the androgen receptor and the mineralocorticoid receptor, partially activated the progesterone B receptor and was not active at the glucocorticoid receptor. Treatment with NTS-105 starting one hour after injury decreased post-traumatic cell death in a dose-dependent manner, with 10 nM NTS-105 being most effective. Post-traumatic administration of 10 nM NTS-105 also prevented deficits in long-term potentiation (LTP) without adversely affecting neuronal activity in naïve cultures. We propose that the high potency pleiotropic action of NTS-105 beneficial effects at multiple receptors (e.g. androgen, mineralocorticoid and progesterone) provides significant mechanistic advantages over native neurosteroids such as progesterone, which lacked clinical success for the treatment of TBI. Our results suggest that this pleiotropic pharmacology may be a promising strategy for the effective treatment of TBI, and future studies should test its efficacy in pre-clinical animal models of TBI.PMI...

Source: Experimental Neurology - November 10, 2023 Category: Neurology Authors: Mary Kate R Dwyer Nicolas Amelinez-Robles Isabella Polsfuss Keondre Herbert Carolyn Kim Nevin Varghese Tom J Parry Benjamin Buller Todd A Verdoorn Clare B Billing Barclay Morrison Source Type: research